Clovis Oncology
CLVS
$0.08120
Share price
0.00%
Change (1 day)
-95.08%
Change (1 year)
Categories
Clovis Oncology (CLVS) - Total liabilities
Total liabilities on the balance sheet as of September 2022 : $0.76 B
According to Clovis Oncology's latest financial reports the company's total liabilities are $0.76 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Clovis Oncology - Total liabilities on balance sheet (from 2010 to 2022)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2021-12-31 | $0.75 B | -1.65% |
| 2020-12-31 | $0.76 B | -9.43% |
| 2019-12-31 | $0.84 B | 17.68% |
| 2018-12-31 | $0.71 B | 95.08% |
| 2017-12-31 | $0.36 B | -0.16% |
| 2016-12-31 | $0.36 B | -10.79% |
| 2015-12-31 | $0.41 B | -9.2% |
| 2014-12-31 | $0.45 B | 199.56% |
| 2013-12-31 | $0.15 B | 1114.19% |
| 2012-12-31 | $12.49 M | 7.26% |
| 2011-12-31 | $11.65 M | -85.61% |
| 2010-12-31 | $80.94 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $98.78 B | 12,818.67% | 🇺🇸 USA |
 Pfizer PFE | $137.21 B | 17,844.29% | 🇺🇸 USA |
 AbbVie ABBV | $124.31 B | 16,157.40% | 🇺🇸 USA |
 Eli Lilly LLY | $53.14 B | 6,849.82% | 🇺🇸 USA |
 AstraZeneca AZN | $64.79 B | 8,373.30% | 🇬🇧 UK |
 BioMarin Pharmaceutical BMRN | $1.89 B | 147.17% | 🇺🇸 USA |